Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
Analysis of revenue contributions from different manufacturers in the market.
Gout Drugs Market
The gout drugs market is an integral segment of the pharmaceutical industry. This industry deals in the manufacturing and distribution of therapeutics for treating gout diseases among people. These drugs are generally used for easing pain and inflammation during a gout attack, and they also find application in lowering uric acid levels in the blood to avoid future gout-related health problems. The main drugs used in gout treatment include allopurinol and febuxostat. Several non-steroid anti-inflammatory drugs are also effective in gout treatment, mainly including naproxen, indomethacin, sulindac, or celecoxib. This market is expected to rise significantly with the growth in the medical sector worldwide.
The increased prevalence of acute and chronic gout disease among the people of the world has increased the demand for effective therapeutics, thereby driving market growth. Also, the growing use of various drug classes such as NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others is likely to shape the industry positively. Moreover, the availability of these drugs in online pharmacies, retail pharmacies, and other places is expected to propel the growth of the gout drugs market.
Advancements in NLRP3 Inhibitors, along with minimizing the immunogenicity of uricase-based therapy, are expected to create ample growth opportunities in the gout drugs market. In August 2023, the US Food and Drug Administration (FDA) approved canakinumab (Ilaris). Canakinumab is a humanized anti-interleukin-1β monoclonal antibody that effectively treats gout disease.
Download
Order Databook
Actionable Solutions
